Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties
Company Announcements

Aclaris Therapeutics Secures Deal with OMERS for OLUMIANT Royalties

Aclaris Therapeutics (ACRS) has provided an update.

Aclaris Therapeutics has struck a lucrative deal with OMERS, selling a portion of its future royalty payments and associated milestones from its license with Eli Lilly for OLUMIANT, a treatment for alopecia areata. The transaction nets Aclaris an immediate $26.5 million, with the potential for an additional $5 million, depending on sales achievements in 2024. OMERS, in return, gains a slice of the ongoing royalty pie from global sales of OLUMIANT, reinforcing its investment portfolio in the healthcare sector. This strategic financial move was also publicized through a press release to keep investors informed.

For an in-depth examination of ACRS stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAclaris Therapeutics Reports Positive Q3 2024 Milestones
TheFlyAclaris Therapeutics reports Q3 EPS (11c), consensus (1c)
Catie PowersACRS Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App